Loncastuximab Tesirine + Rituximab After Radiosurgery

Patients will receive stereotactic radiosurgery (SRS) followed by a brain MRI approx. 3 weeks after SRS. This will be followed by loncastuximab tesirine and rituximab administered intravenously for a total of 6 cycles (every 21 days).

The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.

Live record on ClinicalTrials.gov →

• Participant aged ≥ 18 years
• ECOG Performance Status ≤ 3
• Relapsed or refractory disease with at least 1 prior therapy OR
• Ineligible for high-dose methotrexate-based therapy as determined by the treating physician, including previously untreated patients. Examples of medical conditions for which a patient could be considered ineligible for high-dose methotrexate include but not limited to renal impairment, liver disease, heart failure.
• Note: For patients with a history of histologically documented systemic DLBCL with CNS relapse, a biopsy of the CNS lesion is recommended but not required.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.